科兴制药(688136.SH)：预计2025年净利润同比增加328.83%至455.89%

Core Viewpoint - The company, Sinovac Biotech (688136.SH), expects a significant increase in net profit for the year 2025, driven by strong growth in overseas markets and a substantial rise in operating income [1] Financial Performance - The estimated net profit attributable to the parent company for 2025 is projected to be between 135 million and 175 million yuan, representing an increase of 103.52 million to 143.52 million yuan compared to the previous year, which is a year-on-year increase of 328.83% to 455.89% [1] - The estimated net profit attributable to the parent company after deducting non-recurring gains and losses is expected to be between 50 million and 70 million yuan, reflecting an increase of 14.75 million to 34.75 million yuan compared to the previous year, translating to a year-on-year increase of 41.83% to 98.56% [1] Market Expansion - The company is actively expanding into overseas markets, which has led to strong growth in overseas revenue, contributing to the continuous increase in operating income [1] - The significant changes in non-recurring gains and losses during the reporting period are mainly due to the fair value changes of private equity funds held by the company and the disposal of subsidiaries [1]